Moreover, given the high frequency of CDKN2A and P53 disruption in cancer, a deeper understanding of the molecular and biochemical effects of their role in MPNSTs may inform broader cancer mechanisms and potential therapies. The gene discussed is CDKN2A; the disease is cancer.